5-HT1A 和 5-HT2A/2C 受体在粉防己碱增强戊巴比妥钠睡眠中的介导作用

5-HT1A 和 5-HT2A/2C 受体在粉防己碱增强戊巴比妥钠睡眠中的介导作用

杜楠, 王黎恩, 师晓荣, 崔翔宇, 崔素颖, 张帆, 张永鹤^*

北京大学基础医学院药理学系, 北京 100191

收稿日期:2008-04-20 修回日期:2008-08-10 出版日期:2008-09-15 发布日期:2008-09-15
通讯作者: 张永鹤*

Augmentative effect of tetrandrine on pentobarbital hypnosis mediated by 5-HT1A and 5-HT2A/2C receptors in mice

Nan Du, Li-En Wang, Xiao-Rong Shi, Xiang-Yu Cui, Su-Ying Cui, Fan Zhang, Yong-He Zhang^*

Department of Pharmacology, School of Basic Medical Science, Peking University, Beijing 100191, China

Received:2008-04-20 Revised:2008-08-10 Online:2008-09-15 Published:2008-09-15
Contact: Yong-He Zhang*

摘要/Abstract

摘要：

前期研究表明粉防己碱增强戊巴比妥钠诱导的催眠作用与5-HT系统相关。本研究采用戊巴比妥钠 (45 mg/kg, i.p.)诱导的小鼠翻正反射消失和恢复实验方法, 对粉防己碱与不同5-HT受体在增强戊巴比妥钠诱导睡眠中的相互作用进行了探讨。结果表明粉防己碱分别与选择性5-HT1A受体拮抗剂p-MPPI (1 mg/kg, i.p.), 选择性5-HT2A/2C受体拮抗剂ketanserin (1.5 mg/kg, i.p.)合用可以显著增强戊巴比妥钠诱导的催眠作用。选择性5-HT1A受体激动剂8-OH-DPAT (0.1 mg/kg, s.c.)或5-HT2A/2C受体激动剂DOI (0.2 mg/kg, i.p.)能够显著减少戊巴比妥钠诱导的小鼠睡眠时间, 而粉防己碱(60 mg/kg, i.g.)可以显著拮抗这种睡眠抑制作用。此结果提示, 粉防己碱增强戊巴比妥钠诱导的催眠作用可能与5-HT1A受体和5-HT2A/2C受体有关。

关键词: 粉防己碱, 粉防己碱, 粉防己碱, 戊巴比妥钠催眠作用, 戊巴比妥钠催眠作用, 戊巴比妥钠催眠作用, 5-羟色胺1A受体, 5-羟色胺1A受体, 5-羟色胺1A受体, 5-羟色胺2A/2C受体, 5-羟色胺2A/2C受体, 5-羟色胺2A/2C受体

Abstract: It has been reported that augmentative effect of tetrandrine on pentobarbital hypnosis in mice may be related to serotonergic system. The present study was undertaken to investigate the interaction of tetrandrine and different 5-HT receptors on pentobarbital-induced sleep by using the loss-of-righting reflex method. The results showed that augmentative effect of tetrandrine on pentobarbital hypnosis in mice were potentiated by the p-MPPI (5-HT1A receptor antagonist) (1 mg/kg, i.p.) and ketanserin (5-HT2A/2C receptor antagonist) (1.5 mg/kg, i.p.), respectively. Pretreatment with either 8-OH-DPAT (5-HT1A receptor agonist) (0.1 mg/kg, s.c.) or DOI (5-HT2A/2C receptor agonist) (0.2 mg/kg, i.p.) significantly decreased pentobarbital-induced sleep time, and tetrandrine (60 mg/kg, i.g.) significantly reversed this effect. These results suggest that both the 5-HT1A and 5-HT2A/2C subfamily may be involved in the potentiating mechanism of tetrandrine’s effects on pentobarbital hypnosis.

Key words: Tetrandrine, Tetrandrine, Pentobarbital hypnosis, Pentobarbital hypnosis, 5-HT1A receptor, 5-HT1A receptor, 5-HT2A/2C receptor, 5-HT2A/2C receptor

中图分类号:

R964

Supporting: Foundation items: National Natural Science Foundation of China (Grant No. 30772556 and 30640070); Research Fund of Janssen Research Council and the ‘985’ Project in Peking University.
^*Corresponding author. Tel./fax: 86-10-82801112

杜楠, 王黎恩, 师晓荣, 崔翔宇, 崔素颖, 张帆, 张永鹤^*. 5-HT1A 和 5-HT2A/2C 受体在粉防己碱增强戊巴比妥钠睡眠中的介导作用
[J]. .

Nan Du, Li-En Wang, Xiao-Rong Shi, Xiang-Yu Cui, Su-Ying Cui, Fan Zhang, Yong-He Zhang^*. Augmentative effect of tetrandrine on pentobarbital hypnosis mediated by 5-HT1A and 5-HT2A/2C receptors in mice
[J]. .

参考文献

[1] Kim, H.S.; Zhang, Y.H.; Oh, K.W.; Ahn, H.Y. J. Ethnopharmacol. 1997, 58, 117-123.
[2] Zhao, X.; Cui, X.Y.; Chen, B.Q.; Chu, Q.P.; Yao, H.Y.; Ku, B.S.; Zhang, Y.H. Eur. J. Pharmacol. 2004, 506, 101-105.
[3] Artigas, F.; Romero, L.; Montigny de, C.; Blier, P. Trends Neurosci. 1996, 19, 378-383.
[4] Ramboz, S.; Oosting, R.; Amara, D.A.; Kung, H.F.; Blier, P.; Mendelsohn, M.; Mann, J.J.; Brunner, D.; Hen, R. Proc. Natl. Acad. Sci. USA. 1998, 95, 14476-14481.
[5] Rocha, B.A.; Scearce-Levie, K.; Lucas, J.J.; N. Hiroi, N. Castanon, J.C.; Crabbe, J.C.; Nestler, E.J.; Hen, R. Nature. 1998, 393, 175-178.
[6] Meneses, A.; Neurosci. Biobehav. Rev. 1999, 23, 1111-1125.
[7] Bjorvan, B.; Ursin, R. Res. Neurosci. 1998, 9, 265-273.
[8] Xuan, B.; Liu, F.; Zhang, M.Y.; Xiao, J.G. J. Ocul Pharmacol. Ther. 1996, 12, 331-336.
[9] Zhang, Y.H.; Fang, L.H. Life Sci. 2001, 69, 1429-1439.
[10] Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P.A. Pharmac. Rev. 1994, 46, 157-203.
[11] Dzoljic, M.R.; Ukponmwan, O.E.; Saxena, P.R. Neuropharmacology. 1992, 31, 623-633.
[12] Monti, J.M.; Jantos, H. J. Sleep Res. 1992, 1, 169-175.
[13] Monti, J.M.; Jantos, H. Neuropharmacology. 1994. 33, 705-708.
[14] Kung, M,P.; Frederick, D.; Mu, M.; Zhuang, Z.P.; Kung, H.F. J. Pharmacol. Exp. Ther. 1995, 272, 429-437.
[15] Kung, M,P.; Zhuang, Z.P.; Frederick, D.; Kung, H.F. Synapse. 1994, 18, 359-366.
[16] Allen, A.R.; Singh, A.; Zhuang, Z.P.; Kung, M.P.; Kung, H.F.; Lucki, I. Pharmacol. Biochem. Behav. 1997, 57, 301-307.
[17] Martin, L.P.; Jackson, D.M.; Wallsten, C.; Waszczak, B.L. J. Pharmacol. Exp. Ther. 1999, 288, 820-826.
[18] Thielen, R.J.; Fangon, N.B.; Frazer, A. J. Pharmacol. Exp. Ther. 1996, 277, 661-670.
[19] Thielen, R.J.; Frazer, A. Life Sci. 1995, 56, 163-168.
[20] Sørensen, E.; Grønli, J.; Bjorvatn, B.; Bjørkuma, A.; Ursin, R. Brain Res. 2001, 897, 122-130.
[21] Sørensen, E.; Bjorvatn, B.; Ursin, R. Soc. Neurosci. Abstr. 1998, 695.
[22] Sørensen, E.; Grønli, J.; Bjorvatn, B.; Ursin, R. Brain Res. 2001, 121, 181-187.
[23] Duxon, M.S.; Flanigan, T.P.; Reavley, A.C.; Baxter, G.S.; Blackburn, T.P.; Fone, K.C.F. Neuroscience. 1997, 76, 323-329.
[24] Leysen, J.E. CNS & Neuro. Disorders. 2004, 3, 12-26.
[25] Marazziti, D.; Ori, M.; Nardini, M.; Rossi, A.; Nardi, I.; Cassano, G.B. Neuropsychobiology. 2001, 43, 123-126.
[26] Monti, J.M.; Pineyro, G.; Orellana, C.; Boussard, M.; Jantos, H. Biogenic Amines. 1990, 7, 145-151.
[27] Dugovic, C. J. Sleep Res. 1992, 1, 163-68.
[28] Dugovic, C.; Wauquier, A.; Leysen, J.E.; Marrannes, R.; Janssen, P.A.J. Psychopharmacology. 1989, 97, 436-442.
[29] Amicia, R.; Sanfordb, D.L.; Kearneyb, K.; McInerneyb, B.; Rossc, J.R.; Hornerb, L.R.; Morrisonb, R.A. Brain Res. 2004, 996, 9-18.
[30] Zhao, X.; Cui, X.Y.; Chu, Q.P.; Chen, B.Q.; Wang, X.M.; Lin, Z.B.; Li, X.J.; Ku, B.S.; Zhang, Y.H. J. Neural. Transm. 2006, 113, 1395-1402.